Peptides in Obesity Research: GLP-1 & Beyond
Peptide-based approaches to obesity research have transformed the field, with GLP-1 receptor agonists leading a new era of metabolic research. Understanding the peptide landscape helps researchers choose the right tools for their studies.
GLP-1 Receptor Agonists
Semaglutide — The most studied single GLP-1 agonist in obesity research. Mechanisms include central appetite suppression, delayed gastric emptying, and improved insulin sensitivity. Tirzepatide — Dual GIP/GLP-1 agonist showing enhanced metabolic effects through complementary receptor activation. Retatrutide — Triple agonist (GLP-1/GIP/glucagon) representing the next frontier in multi-target metabolic peptide research.
Fat Metabolism Peptides
AOD 9604 — A modified fragment of human growth hormone (HGH 176-191) that stimulates lipolysis without the growth-promoting effects of full HGH. MOTS-C — Mitochondrial-derived peptide that activates AMPK, improving metabolic efficiency and mimicking exercise-like metabolic effects.
Multi-Target Approaches
Modern obesity peptide research increasingly focuses on multi-target compounds. The progression from single (semaglutide) to dual (tirzepatide) to triple (retatrutide) agonists demonstrates the trend toward addressing obesity through multiple complementary pathways simultaneously.
Future Directions
Emerging areas include: oral GLP-1 compounds, combination peptide therapies, muscle-sparing weight loss approaches, and personalized metabolic peptide protocols.
Related Articles: Semaglutide for Weight Loss | Best Fat Loss Peptides | Weight Loss Research 2026
For research use only. Shop metabolic peptides with verified COAs at Proxiva Labs.